These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 20193104)
21. Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis. Pallini R; Ricci-Vitiani L; Montano N; Mollinari C; Biffoni M; Cenci T; Pierconti F; Martini M; De Maria R; Larocca LM Cancer; 2011 Jan; 117(1):162-74. PubMed ID: 20806346 [TBL] [Abstract][Full Text] [Related]
22. Co-expression of putative cancer stem cell markers, CD133 and Nestin, in skin tumors. Sabet MN; Rakhshan A; Erfani E; Madjd Z Asian Pac J Cancer Prev; 2014; 15(19):8161-9. PubMed ID: 25339000 [TBL] [Abstract][Full Text] [Related]
24. Differential Expression of Cancer Stem Cell Markers ALDH1 and CD133 in Various Lung Cancer Subtypes. Roudi R; Korourian A; Shariftabrizi A; Madjd Z Cancer Invest; 2015; 33(7):294-302. PubMed ID: 26046383 [TBL] [Abstract][Full Text] [Related]
25. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Soeda A; Park M; Lee D; Mintz A; Androutsellis-Theotokis A; McKay RD; Engh J; Iwama T; Kunisada T; Kassam AB; Pollack IF; Park DM Oncogene; 2009 Nov; 28(45):3949-59. PubMed ID: 19718046 [TBL] [Abstract][Full Text] [Related]
26. CD133 expression is correlated with chemoresistance and early recurrence of gastric cancer. Lee HH; Seo KJ; An CH; Kim JS; Jeon HM J Surg Oncol; 2012 Dec; 106(8):999-1004. PubMed ID: 22674531 [TBL] [Abstract][Full Text] [Related]
27. [Preliminary interpretation on the relationship between the phenotype of CD133+ cells and niche in transplanted human glioma in mice]. Song WC; Fei XF; Dong J Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):564-9. PubMed ID: 21122405 [TBL] [Abstract][Full Text] [Related]
28. CD133: holy of grail of neuro-oncology or promiscuous red-herring? Donovan LK; Pilkington GJ Cell Prolif; 2012 Dec; 45(6):527-37. PubMed ID: 23106300 [TBL] [Abstract][Full Text] [Related]
29. Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression. Gambelli F; Sasdelli F; Manini I; Gambarana C; Oliveri G; Miracco C; Sorrentino V Cell Biol Int; 2012 Jan; 36(1):29-38. PubMed ID: 21916848 [TBL] [Abstract][Full Text] [Related]
30. Galectin-1 is overexpressed in CD133+ human lung adenocarcinoma cells and promotes their growth and invasiveness. Zhou X; Li D; Wang X; Zhang B; Zhu H; Zhao J Oncotarget; 2015 Feb; 6(5):3111-22. PubMed ID: 25605013 [TBL] [Abstract][Full Text] [Related]
31. CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme. Choy W; Nagasawa DT; Trang A; Thill K; Spasic M; Yang I Neurosurg Clin N Am; 2012 Jul; 23(3):391-405. PubMed ID: 22748652 [TBL] [Abstract][Full Text] [Related]
32. Limits of CD133 as a marker of glioma self-renewing cells. Clément V; Dutoit V; Marino D; Dietrich PY; Radovanovic I Int J Cancer; 2009 Jul; 125(1):244-8. PubMed ID: 19350631 [TBL] [Abstract][Full Text] [Related]
33. CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non-small cell lung cancer. Cui F; Wang J; Chen D; Chen YJ Oncol Rep; 2011 Mar; 25(3):701-8. PubMed ID: 21174061 [TBL] [Abstract][Full Text] [Related]
34. Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression. Skubitz AP; Taras EP; Boylan KL; Waldron NN; Oh S; Panoskaltsis-Mortari A; Vallera DA Gynecol Oncol; 2013 Sep; 130(3):579-87. PubMed ID: 23721800 [TBL] [Abstract][Full Text] [Related]
35. Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy. Kubo T; Takigawa N; Osawa M; Harada D; Ninomiya T; Ochi N; Ichihara E; Yamane H; Tanimoto M; Kiura K Cancer Sci; 2013 Jan; 104(1):78-84. PubMed ID: 23066953 [TBL] [Abstract][Full Text] [Related]
36. [An update: stem cell and cancer stem cells]. Liu YQ Zhonghua Bing Li Xue Za Zhi; 2009 Aug; 38(8):511-2. PubMed ID: 20021959 [No Abstract] [Full Text] [Related]
37. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer. Wang Q; Chen ZG; Du CZ; Wang HW; Yan L; Gu J Histopathology; 2009 Sep; 55(3):284-93. PubMed ID: 19723143 [TBL] [Abstract][Full Text] [Related]
38. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Curley MD; Therrien VA; Cummings CL; Sergent PA; Koulouris CR; Friel AM; Roberts DJ; Seiden MV; Scadden DT; Rueda BR; Foster R Stem Cells; 2009 Dec; 27(12):2875-83. PubMed ID: 19816957 [TBL] [Abstract][Full Text] [Related]
39. Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer. Qin Q; Sun Y; Fei M; Zhang J; Jia Y; Gu M; Xia R; Chen S; Deng A Neoplasma; 2012; 59(3):310-5. PubMed ID: 22296500 [TBL] [Abstract][Full Text] [Related]
40. The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. Horst D; Scheel SK; Liebmann S; Neumann J; Maatz S; Kirchner T; Jung A J Pathol; 2009 Dec; 219(4):427-34. PubMed ID: 19621338 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]